CAPTRUST Financial Advisors
TBPH icon

CAPTRUST Financial Advisors’s Theravance Biopharma TBPH Stock Holding History

CAPTRUST Financial Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-91
Closed -$1K – 3835
2022
Q2 		$1K Hold
91
– – ﹤0.01% 4749
2022
Q1 		$1K Sell
91
-278
-75% -$2.72K ﹤0.01% 4751
2021
Q4 		$4K Buy
+369
New +$3.22K ﹤0.01% 4191
2021
Q3 		– Sell
-31
Closed – – 4759
2021
Q2 		$0 Hold
31
– – ﹤0.01% 4650
2021
Q1 		$1K Buy
+31
New +$589 ﹤0.01% 4238

Other funds holding TBPH

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAPTRUST Financial Advisors's TBPH Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Theravance Biopharma (TBPH) in Q3 2022, closing a stake of 91 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in TBPH in Q1 2021 and held it in 5 quarters. The position peaked at $4K in Q4 2021. 123 funds tracked by Wall St. Rank hold TBPH as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Theravance Biopharma position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 91 Theravance Biopharma shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Theravance Biopharma in Q1 2021 and held it in 5 quarters.
  • CAPTRUST Financial Advisors's Theravance Biopharma position peaked at $4K in Q4 2021.
  • 123 funds tracked by Wall St. Rank held Theravance Biopharma as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.